Advertisement
Advertisement

SRPT

SRPT logo

Sarepta Therapeutics,, Inc. Common Stock

21.55
USD
Sponsored
+0.38
+1.79%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

21.53

-0.02
-0.09%

Sarepta Therapeutics,, Inc. Common Stock Profile

About

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.

Info & Links

CEO

Douglas S. Ingram

Headquarters

215 FIRST STREET, SUITE 415
CAMBRIDGE, MA 02142, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.sarepta.com

Auditor

KPMG LLP

Share holders

140

Employees

835

Sarepta Therapeutics,, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

2.26B

Enterprise Value

2.29B

Enterprise Value/EBITDA(ttm)

-3.46

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.06

Price to Book(mrq)

2.04

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

57.20%

Operating Margin(ttm)

-28.63%

Profit Margin(ttm)

-34.19%

Return on Equity(ttm)

-50.74%

Return on Invested Capital(ttm)

-33.73%

Return on Assets(ttm)

-18.00%

Income Statement

Revenue(ttm)

2.20B

Revenue Per Share(ttm)

20.94

Gross Profit(ttm)

1.36B

EBITDA(ttm)3

-660.55M

Net Income Available to Common(ttm)

-713.41M

Diluted EPS(ttm)

-8.44

Share Statistics

Beta (5Y Monthly)

0.29

52-Week Change

-59.94%

S&P 500 52-Week Change

38.15%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

104.99M

Dividend Yield

0.00%

Float4

97.01M

% Held by Insiders

7.60%

% Held by Institutions

86.68%

Balance Sheet

Total Cash(mrq)

939.65M

Total Cash Per Share(mrq)

8.95

Total Debt(mrq)

828.97M

Total Debt/Equity(mrq)

72.68%

Current Ratio(mrq)

2.32%

Quick Ratio(mrq)

1.48%

Book Value Per Share(mrq)

10.87

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.05

Free Cash Flow(ytd)

-307.45M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement